January 06, 2020 – Lab Bioreagents, a biotechnology company developing assay reagents and kits to support drug development, today announced the upgrade of multiple products. In the support of investor, Lab Bioreagents upgrades the manufacture system for assay buffers including buffer size, product labeling and price.

“I am glad to deliver this great news to our customers” said David Toil, Ph.D., Chief Executive Officer of Lab Bioreagents. “Through versatile buffer availability, improved labeling and attractive price, we hope to further support the various needs from our clients".